Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Page 2 of 10
Risk factors for thrombosis include hypoxia and sepsis, but the mechanisms that control sepsis-induced thrombus formation are incompletely understood. A recent article published in Thrombosis Journal: (i) revi...
Citation: Thrombosis Journal 2019 17:16
Bridging anticoagulation is used in vitamin-K antagonist (VKA) patients undergoing invasive procedures and involves complex risk assessment in order to prevent thromboembolic and bleeding outcomes.
Citation: Thrombosis Journal 2019 17:15
Ambulatory management of isolated acute deep venous thrombosis (DVT) is the recommended standard of care in selected populations. However, in practice a significant number of patients continue to be managed as...
Citation: Thrombosis Journal 2019 17:14
Although patients with acute myeloid leukemia (AML) were shown to have an increased risk of thrombosis, no thrombosis risk assessment scoring system has been developed for AML patients. The Khorana Risk Score ...
Citation: Thrombosis Journal 2019 17:13
The usefulness of the activated partial thromboplastin time (APTT) waveform has been reported in hemophilia, acquired hemophilia and monitoring for anticoagulants.
Citation: Thrombosis Journal 2019 17:12
Venous thromboembolism (VTE) of the lower limbs is an important complication post total knee arthroplasty (TKA). Current guidelines recommend routine chemical prophylaxis to all patients undergoing this proced...
Citation: Thrombosis Journal 2019 17:9
Endocardial Fibroelastosis is diffuse, accentuated proliferation of ventricular endocardium causing a rare form of restrictive cardiomyopathy in both children and adults. It is an incompletely understood cause...
Citation: Thrombosis Journal 2019 17:8
In addition to protective “immune response”, sepsis is characterized by destructive “endothelial response” of the host, leading to endotheliopathy and its molecular dysfunction. Complement activation generates...
Citation: Thrombosis Journal 2019 17:10
Platelet inhibition is important for patients with coronary artery disease. When dual antiplatelet therapy (DAPT) is required, a P2Y12-antagonist is usually recommended in addition to standard aspirin therapy. Th...
Citation: Thrombosis Journal 2019 17:11
Real-world data on non-vitamin K oral anticoagulants (NOACs) are essential in determining whether evidence from randomised controlled clinical trials translate into meaningful clinical benefits for patients in...
Citation: Thrombosis Journal 2019 17:7
Clinical practice shows that venous thromboembolism (VTE) presents a substantial burden in medical patients, and awareness and advocacy for its primary and secondary prevention remains inadequate. Specific pat...
Citation: Thrombosis Journal 2019 17:6
Following the publication of this article [1], the authors noted the following typographical errors.
Citation: Thrombosis Journal 2019 17:5
Inflammatory diseases have become increasingly prevalent with industrialization. To address this, numerous anti-inflammatory agents and molecular targets have been considered in clinical trials. Among molecula...
Citation: Thrombosis Journal 2019 17:4
This study involved a sensory evaluation of edoxaban orally disintegrating (OD) tablets in patients with nonvalvular atrial fibrillation who had been receiving the existing edoxaban film-coated tablets before ...
Citation: Thrombosis Journal 2019 17:3
Peripherally inserted central catheters(PICC) lines are becoming increasingly popular in solid cancer patients for the administration of chemotherapy. This study aims looking at the incidence of PICC line rela...
Citation: Thrombosis Journal 2019 17:2
Nuclear histone proteins are released into the extracellular space, and act as major mediators of coagulopathy and remote organ failure in septic animals. However, the circulating histone levels in septic pati...
Citation: Thrombosis Journal 2019 17:1
Venous thromboembolism (VTE) is a relatively rare condition in childhood with treatment mainly based on extrapolation from studies in adults. Therefore, clinical trials of anticoagulation in children require n...
Citation: Thrombosis Journal 2018 16:34
Splanchnic Vein Thrombosis (SVT) is strongly associated with underlying JAK2 V617F positive myeloproliferative neoplasms (MPN).
Citation: Thrombosis Journal 2018 16:33
The thrombotic microangiopathies (TMAs) is a heterogeneous group of relatively uncommon but serious disorders presenting with thrombocytopenia and microangiopathic haemolysis. Thrombotic thrombocytopenic purpu...
Citation: Thrombosis Journal 2018 16:35
The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults. A physiologically based pha...
Citation: Thrombosis Journal 2018 16:32
The EINSTEIN-Jr program will evaluate rivaroxaban for the treatment of venous thromboembolism (VTE) in children, targeting exposures similar to the 20 mg once-daily dose for adults.
Citation: Thrombosis Journal 2018 16:31
Autoimmune paraphenomena, are associated with B-cell lymphoproliferative disorders, including monoclonal gammopathy of uncertain significance. These paraphenomena can rarely include acquired bleeding disorders.
Citation: Thrombosis Journal 2018 16:30
Serious bleeding events have been frequently described in patients taking direct oral anticoagulants (DOAC). In secondary analyses of phase 3 trials, DOAC plasma concentrations were shown to correlate with ble...
Citation: Thrombosis Journal 2018 16:28
Venous thromboembolism (VTE) in young children is not well documented.
Citation: Thrombosis Journal 2018 16:29
Five patients with paroxysmal nocturnal haemoglobinuria and thrombotic complications under oral antithrombotic treatment with vitamin K antagonist were switched to receive the direct oral anticoagulant rivarox...
Citation: Thrombosis Journal 2018 16:26
A majority of deep vein thromboses identified in screening studies of hospitalized patients remain clinically insignificant. Guidelines based on these studies markedly overestimate the risk of clinical venous ...
Citation: Thrombosis Journal 2018 16:25
Globally, sickle cell disease (SCD) is one of the most common haemoglobinopathy. Considered a public health problem, it leads to vessel occlusion, blood stasis and chronic activation of the coagulation system ...
Citation: Thrombosis Journal 2018 16:27
Recombinant human soluble thrombomodulin (rTM) has been used for the treatment of disseminated intravascular coagulation in Japan, and an international phase III clinical trial for rTM is currently in progress...
Citation: Thrombosis Journal 2018 16:24
Atrial fibrillation (AF) is a major risk factor for stroke as it increases the incidence of stroke nearly fivefold. Antithrombotic treatment is recommended for the prevention of stroke in AF patients. However,...
Citation: Thrombosis Journal 2018 16:22
Around 20% of venous thromboembolism (VTE) cases occur in patients with cancer. Current guidelines recommend low molecular weight heparin (LMWH) as the preferred anticoagulant for VTE treatment. However, some ...
Citation: Thrombosis Journal 2018 16:21
Anticoagulation therapy for mechanical prosthetic valves is limited to vitamin K antagonists, unfractionated heparin and low-molecular-weight-heparin. Other forms of anticoagulation are either contraindicated ...
Citation: Thrombosis Journal 2018 16:23
Disseminated intravascular coagulation (DIC) is associated with high mortality in patients with sepsis. Several studies reporting that recombinant human soluble thrombomodulin (rhTM) reduced mortality in sepsi...
Citation: Thrombosis Journal 2018 16:19
TTP is characterized by microangiopathic hemolytic anemia and thrombocytopenia associated with brain and kidney dysfunction. It occurs due to ADAMTS13 deficiency. TTP-like syndrome occurs in critically ill pat...
Citation: Thrombosis Journal 2018 16:20
We conducted a prospective observational study for investigating coagulofibrinolytic changes and mechanisms of antithrombin (AT) alternations in trauma.
Citation: Thrombosis Journal 2018 16:17
Platelets are small non-nucleated cell fragments and the second most abundant cell that play crucial role in managing vascular integrity and regulating hemostasis. Recent finding shows, beyond its hemostatic f...
Citation: Thrombosis Journal 2018 16:16
Both disseminated intravascular coagulation (DIC) and thrombotic microangiopathy (TMA) cause microvascular thrombosis associated with thrombocytopenia, bleeding tendency and organ failure.
Citation: Thrombosis Journal 2018 16:14
Hyponatremia is common among patients with pulmonary embolism, while hypernatremia increases the risk of venous thromboembolism (VTE). Our objective was to evaluate the association between sodium imbalances an...
Citation: Thrombosis Journal 2018 16:11
The pathophysiological mechanisms of acute coagulopathy of trauma-shock (ACOTS) are reported to include activated protein C-mediated suppression of thrombin generation via the proteolytic inactivation of activ...
Citation: Thrombosis Journal 2018 16:13
Small studies have implicated plasminogen activator inhibitor-1 (PAI-1) as a predictor of cardiovascular events; however, these findings have been inconsistent.
Citation: Thrombosis Journal 2018 16:12
Correction to: Thrombosis Journal (2018) 16:9 DOI 10.1186/s12959-018-0163-7
Citation: Thrombosis Journal 2018 16:18
Accurate thrombin generation determination by calibrated automated thrombinography can be sustained when reducing the plasma and reagent volumes up to half, but not for higher reductions or plasma dilutions.
Citation: Thrombosis Journal 2018 16:10
Venous thromboembolism (VTE, including deep vein thrombosis [DVT] and pulmonary embolism [PE]) has an annual incidence rate of 104–183 per 100,000 person-years. After a VTE episode, the two-year recurrence rat...
Citation: Thrombosis Journal 2018 16:9
Following the publication of this study [1] the authors identified the following errors inadvertently introduced during the production process:
Citation: Thrombosis Journal 2018 16:15
In 2012, around 400.000 patients in the Netherlands were treated with Vitamin K Antagonists (VKA) for thromboembolic diseases. Since 2011, non-VKA oral anticoagulants (NOACs) are available. NOACs do not requir...
Citation: Thrombosis Journal 2018 16:7
Patients with congenital afibrinogenemia suffer from spontaneous recurrent severe bleeding. While fibrinogen concentrates are known to effectively treat bleeding episodes, thrombotic complications often occur ...
Citation: Thrombosis Journal 2018 16:6
Although prasugrel exerts stronger antiplatelet effects compared with clopidogrel, the factors affecting platelet reactivity under prasugrel have not been fully determined. This study aimed to find the novel m...
Citation: Thrombosis Journal 2018 16:5
The risk of thromboembolic events is higher among cancer patients, especially in patients undergoing chemotherapy. Cisplatin-based regimens claim to be associated with a very high thromboembolic rate. In this ...
Citation: Thrombosis Journal 2018 16:2
An incidental/unsuspected diagnosis of pulmonary embolism (IPE) in cancer patients is a frequent occurrence. This single-institution analysis of uniformly managed patients investigates short and long-term outc...
Citation: Thrombosis Journal 2018 16:8
Traditional coagulation tests are included in emergency guidelines for management of patients on direct oral anticoagulants (DOACs) who experience acute bleeding or require surgery. We determined the ability o...
Citation: Thrombosis Journal 2018 16:3
Although the incidence of venous thromboembolism (VTE) in Asian populations is lower than in Western countries, the overall burden of VTE in Asia has been considerably underestimated. Factors that may explain ...
Citation: Thrombosis Journal 2018 16:4
Thrombosis Journal is the official journal of the Asian-Pacific Society on Thrombosis and Hemostasis.
Members of APSTH are entitled to a 15% discount on the article processing charge.
Speed
51 days to first decision for reviewed manuscripts only
48 days to first decision for all manuscripts
102 days from submission to acceptance
45 days from acceptance to publication
Citation Impact
2.295- Impact Factor
1.235 - Source Normalized Impact per Paper (SNIP)
10.895 - SCImago Journal Rank (SJR)
Usage
270,557 Downloads
242 Altmetric mentions